Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.23.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Beginning balance at Jan. 31, 2022 $ 42,524   $ 25 $ 266,112 $ (227) $ (973) $ (222,413)  
Beginning balance, Shares at Jan. 31, 2022     2,467,380          
Issuance of common stock pursuant to vesting of stock units, shares     3,556          
Stock-based compensation expense 284     284        
Foreign currency translation adjustments (576)         (576)    
Net loss (2,996)           (2,996)  
Ending balance at Apr. 30, 2022 39,236   $ 25 266,396 (227) (1,549) (225,409)  
Ending balance, Shares at Apr. 30, 2022     2,470,936          
Beginning balance at Jan. 31, 2023 31,211   $ 25 267,120 (227) (1,890) (233,817)  
Beginning balance, Shares at Jan. 31, 2023     2,519,319          
Issuance of common stock pursuant to vesting of stock units, shares     14,163          
Stock-based compensation expense 361     361        
Unrealized losses on marketable securities (10)         (10)    
Foreign currency translation adjustments 105         105    
Net loss (714)           (714)  
Ending balance at Apr. 30, 2023 $ 30,735 $ (218) $ 25 $ 267,481 $ (227) $ (1,795) $ (234,749) $ (218)
Ending balance, Shares at Apr. 30, 2023     2,533,482